Scherm­afbeelding 2025 06 26 om 10.20.10

Nova biomedical | Advanced Test Menu for Critical Care

The Modern Critical Care Profile Prime Plus provides the most clinical value of any blood gas/critical care analyzer by adding essential tests for kidney function (BUN, Creatinine, eGFR), plasma volume (ePV), ionized magnesium (iMg) and MCHC.

AdobeStock 1535491428

The evolving paradigm of delayed cerebral ischemia

A comprehensive review of diagnostic and monitoring strategies Delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage is a multifactorial syndrome extending beyond large-vessel vasospasm. This review explores the evolving diagnostic and monitoring landscape, emphasizing a shift toward multimodal monitoring techniques that detect microcirculatory failure, spreading depolarizations, and metabolic distress.

AdobeStock 780465909

Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia

Assessment of minimal residual disease during B-cell precursor acute lymphoblastic leukemia provides a good indication of therapy response and prognosis. This investigation can be done in several ways, including flow cytometry. Techniques in this field have developed in recent years and CLI chatted to Dr van der Velden (Department of Immunology, Erasmus University Medical Center, […]

tumor diagnostics

AI model detects more than 170 types of cancer with remarkable precision

Researchers at Charité – Universitätsmedizin Berlin have developed crossNN, an artificial intelligence model that can classify more than 170 cancer types using DNA methylation patterns. The system achieves 99.1% precision for brain tumours and 97.8% for pan-cancer classification, working across multiple sequencing platforms including nanopore technology.

droplet on demand

Researchers develop precision droplet-on-demand system for microfluidics

A new pressure-driven method for generating individual droplets at microfluidic T-junctions offers precise temporal control over droplet formation. The technique, validated through theoretical modelling and experimental testing, promises to advance lab-on-a-chip technologies for chemical analysis, diagnostics, and biological research applications.

AdobeStock 37033405

Revvity breaks new ground with FDA-approved reference standards for precision oncology

Cancer diagnostics laboratories have gained a powerful new tool in the fight against genomic complexity. Revvity has unveiled its first FDA-compliant IVD Mimix reference standards, engineered to revolutionise quality control in next-generation sequencing and droplet digital PCR workflows for oncology applications.

Dr Emily Richardson, Lead Scientist, Safety and Toxicology at CN Bio

CN Bio expands liver toxicity testing with cross-species organ-on-a-chip models

Cambridge-based biotechnology company CN Bio has enhanced its industry-leading drug-induced liver injury (DILI) assay with new animal microphysiological system models, enabling comparative toxicity studies across human, rat, and dog liver models to improve preclinical drug safety predictions.

Scherm­afbeelding 2025 06 25 om 14.09.15

BioSkryb Genomics partnership delivers high- throughput single-cell multiomics workflow

BioSkryb Genomics and Tecan Group have unveiled an integrated single-cell multiomics workflow that promises to transform highthroughput cellular analysis. The partnership combines BioSkryb’s ResolveOME™ Whole Genome and Transcriptome Single-Cell Core Kit in 384-well format with Tecan’s Uno Single Cell Dispenser™, enabling parallel analysis of hundreds to thousands of individual cells whilst significantly reducing manual intervention.

AdobeStock 454252902

Spring Bio Solution launches intelligence platform to streamline generic drug development

Spring Bio Solution has unveiled NCE Grid, described as the world’s first free NCE-1 intelligence platform designed to decode and centralise Paragraph IV filing opportunities for generic pharmaceutical companies. The Somerset, New Jersey-based company launched the platform to address what it identifies as significant inefficiencies in current drug development intelligence gathering.

AdobeStock 1156704427

Biognosys unveils next-generation proteomics software with breakthrough immunopeptidomics capabilities

Swiss proteomics leader Biognosys has launched two major software updates that promise to revolutionise mass spectrometry-based protein analysis, with particular advances in immunopeptidomics research critical for therapeutic development.